Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other solid neoplasm 1NET 1Gynecologic 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Small Cell Lung Carcinoma 25Lung Neoplasms 5Carcinoma, Non-Small-Cell Lung 3Neoplasms 2Mesothelioma 2Stomach Neoplasms 1Sarcoma 1SCLC, Extensive Stage 1Recurrence 1Ovarian Neoplasms 1Neutropenia 1Neuroendocrine Tumors 1Mesothelioma, Malignant 1Glioblastoma 1Gastro-enteropancreatic neuroendocrine tumor 1Extensive Stage Small Cell Lung Cancer (ES-SCLC) 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Small Cell 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1

Interventions

zimberelimab 1regorafenib 1PM 01183 1Irinotecan 1Clinical Trials, Phase II as Topic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastro-enteropancreatic neuroendocrine tumor × PM 01183 × Thoracic × Clear all
NCT02611024 2025-07-09

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

PharmaMar

Phase 1/2 Completed
316 enrolled
CNSEndocrineGastrointestinalGynecologicNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Ovarian Epithelial, Glioblastoma, Mesothelioma, Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡